Medicare Improperly Paying for Erectile Dysfunction Drugs

Erectile dysfunction drugs are banned from Medicare spending but a new report from the Department of House and Human Services Office of Inspector General shows that the the program improperly used $3.1 million in gross Medicare Part D drug costs for erectile dysfunction during 2007 and 2008.  While the number pales in comparison to the total gross drug costs estimated at $133 billion for the two years, federal requirements dictate that Part D should not have covered the drugs.  The Centers for Medicare & Medicaid Services (CMS) responded that the dispensing was in error by way of its data processing and database system and that it would be updating the system to prevent the coverage errors.  The report also suggests the creation and maintenance of a list of prohibited drugs to which CMS stated it was unnecessary. 

Download the complete report (PDF)